4.6 Article

Modulation of notch signaling elicits signature tumors and inhibits Hras1-induced oncogenesis in the mouse mammary epithelium

Journal

AMERICAN JOURNAL OF PATHOLOGY
Volume 165, Issue 2, Pages 695-705

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0002-9440(10)63333-0

Keywords

-

Categories

Funding

  1. NCI NIH HHS [CA97403, R01 CA098402, P01 CA097403, T32 CA009503, T32 CA09503, CA098402] Funding Source: Medline
  2. NIGMS NIH HHS [R01 GM062931, GM62931] Funding Source: Medline
  3. NINDS NIH HHS [NS26084, R01 NS026084, R37 NS026084] Funding Source: Medline

Ask authors/readers for more resources

Deregulation of Notch signaling, which normally affects a broad spectrum of cell fates, has been implicated in various neoplastic conditions. Here we describe a transgenic mouse model, which demonstrates that expression of a constitutively active form of the Notch1 receptor in the mammary epithelium induces the rapid development of pregnancy/lactation-dependent neoplasms that consistently exhibit a characteristic histopathological pattern. These signature tumors retain the ability to respond to apoptotic stimuli and regress on initiation of mammary gland involution, but eventually appear to progress in subsequent pregnancies to nonregressing malignant adenocarcinomas. Additionally, we present evidence indicating that cyclin D1 is an in vivo target of Notch signals in die mammary glands and demonstrate that we can effectively inhibit Hras1-driven, cyclin D1-dependent mammary oncogenesis by transgenic expression of the Notch antagonist Deltex.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available